US Pharma MarketingApnimed files for IPO as FDA reviews its sleep apnea drug
Apnimed files for Nasdaq IPO under the ticker $APMD, three months after submitting its sleep apnea drug AD109 for FDA approval. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
Apnimed is finally going forward with an IPO attempt after years of flirting with the milestone.
The Cambridge, MA-based biotech revealed its Nasdaq plans on Friday night, following a strong six ...
Source: Endpoints News